A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial - Wikidata - wikimedia - TriplyDB

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

http://www.wikidata.org/entity/Q27488963

about

Mechanism and significance of cell type-dependent neutralization of flaviviruses Vaccine protection against Zika virus from Brazil Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype Vaccines in development against West Nile virus Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization Closing the door on flaviviruses: Entry as a target for antiviral drug design A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters Plant-made vaccines against West Nile virus are potent, safe, and economically feasible Vaccination strategies against Zika virus Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules.DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.Phase 1 study of pandemic H1 DNA vaccine in healthy adults Prospects for control of emerging infectious diseases with plasmid DNA vaccines.Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics.The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum Bioinformatics in new generation flavivirus vaccines.Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.Rapid development of a DNA vaccine for Zika virus Highly conserved residues in the helical domain of dengue virus type 1 precursor membrane protein are involved in assembly, precursor membrane (prM) protein cleavage, and entry.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial Current trends in West Nile virus vaccine development.A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.The C-terminal helical domain of dengue virus precursor membrane protein is involved in virus assembly and entry.Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling.Sculpting humoral immunity through dengue vaccination to enhance protective immunity Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses.A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.West Nile virus: A re-emerging pathogen revisited.

P2860

Q23032973-61F310D3-92C7-4054-A60D-9FEB26CD6CD3 Q25165129-3896F1A8-CDCA-48CE-8D8C-9F9688CC5D56 Q26252060-714CA13A-4FAD-4871-8B7D-23D4036B625E Q26999702-727D5319-45C1-4E17-B300-6CF181D9753A Q27304342-1F7459A9-0ED4-4BC3-938D-5819D54BA744 Q27485890-063BB038-3601-4987-AA9D-C550C9DF466F Q27487953-A6B5E9DB-D22D-4751-B57B-235E033AE62C Q27487992-A87C08CE-333F-487A-9BDB-1D2D2782A933 Q27490208-8B760B31-5EFE-4E62-A1E2-A902ACB63222 Q28082778-C5782776-904B-45E1-8D8A-31CB64A5C935 Q29571224-77E88FFC-CA7A-49A7-96AB-D713359F9096 Q30204348-FB64A4C9-E2B7-4AE0-A3E4-220DE13ABDFF Q30352934-FCC15558-EED8-498A-AC57-1B0C152BAC79 Q30373824-DA12C63C-E68E-4C3E-95F7-660B455DB46C Q30380454-3FBA9ECD-A9A4-4232-98F2-171BAC08D00B Q32183208-76909C9E-D001-4129-94EE-ACD4C8CEA179 Q33826597-AE8243BE-DD43-4E51-846A-CC83161A8C10 Q33839001-9010AB1A-E995-460E-9A68-2F3407C056F1 Q33880730-787B262B-5FA5-43F4-B09B-9EFF5DA3BE43 Q33909344-5B2764FF-11B6-477A-93E3-CF70AE743288 Q33911897-1D379DCF-212B-4784-8507-A942C0063C10 Q34154300-EE2239E2-21C5-4BE7-815F-1CC0409A048A Q34242499-EB1A0467-748F-4672-82FE-503B76D25C38 Q34263835-4CE46225-04FD-416B-BDDF-2540D9BE5AC3 Q34407701-8D8F4230-582D-4D42-AF07-1895D33D5838 Q34542032-1DB57D70-2450-4FD4-8F53-31AFE4BBA091 Q34580259-D35EFF60-E1C6-406A-96B8-131079513D87 Q34663554-AB0D1E47-0BBE-4B99-957A-90E6528B1A41 Q34788758-6AE95E4F-34F9-45E2-A9E3-BCE9DE9C99BE Q34833926-86F318B5-EC2D-46D4-8E1A-C3FBAC1FE4FC Q35000217-140FD674-CD8C-4F06-99C4-19DD359653ED Q35055198-86E68629-E3B1-4FDE-A5A6-782EAC7810A3 Q35076656-F397CBA2-9B31-4CC9-8BE7-2605AA8AE5E7 Q35742553-8BD41DF4-8877-439F-9D9A-26D70A9F67D5 Q36382589-3C855031-8382-4DEB-90C1-A8532B468071 Q36573064-F231D0DF-DABE-4B1F-A83A-69B965A5FCEC Q36697323-A1788C55-C6F1-4011-A627-3A6A1A5C6B33 Q37033726-0B34A272-F676-4885-B80A-F7E41392B557 Q37087027-6554256F-F27D-4A23-8038-A02E484AEE0C Q37195527-8641B079-3A10-49C8-87BC-1E4AC346EC72

P2860

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

http://www.wikidata.org/entity/Q27488963

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@ast

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@en

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@nl

type

label

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@ast

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@en

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@nl

prefLabel

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@ast

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@en

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@nl

P1433

Q27488963-42AF715F-F153-4B68-B259-0ECC4FEBABCC

P1476

Q27488963-8D6E23A5-07CC-4672-B68C-240EFE7F5917

P2093

Q27488963-18B9E422-EF8C-41CA-B501-1B9567048640

Q27488963-27CB3961-A835-464B-9A34-402EE9832023

Q27488963-3272DFD8-30A0-424A-B4AA-3ACA5F3A563A

Q27488963-41DA63C0-5B43-43A8-B23E-CD5B6FFFB01C

Q27488963-4434FE97-D01C-4ADA-A25D-71DCE25A528E

Q27488963-46C16D09-EF8D-46E4-A357-8B7AA96BD6A1

Q27488963-5E43AED2-35DA-4DE0-9577-099D7761EDAD

Q27488963-6B86A284-DC1E-4228-ACE6-8D9A60795DAD

Q27488963-7442FCAD-8559-4BB1-A1D2-49DB4F969130

Q27488963-8D14238F-593D-44AE-B13A-80A4C5A4FA99

P2860

Q27488963-080C9D37-C1A5-49B4-AB7C-F37085E57585

Q27488963-0EDF97FE-56A6-4716-A23D-DE1DFC826A20

Q27488963-2495EC90-38DA-48DE-B8D9-2574EFB7FACF

Q27488963-2BF180DD-3DE0-479F-ADAD-56F013CA5C44

Q27488963-2C53CA5B-08E0-4D9A-8CA1-D5A498581F1C

Q27488963-32E3241C-2B67-4B6C-8B12-3F11EFBB8CA8

Q27488963-3F7309B4-6204-4AA4-BB69-8650FFE474F6

Q27488963-4150F0A2-447E-4294-B303-625783746B39

Q27488963-4A2BA9A1-8E4B-4214-95F2-96C0E3EA881A

Q27488963-557984F3-3ED5-4C58-9046-E5D989926F3B

P304

Q27488963-8C6F46AC-81A0-4E3B-8450-70E3DA0E3308

P31

Q27488963-E783881D-5E16-4D37-8C49-7200916ACE25

P3181

Q27488963-ECBF110F-4A59-4C98-8A16-386D61E62E73

P356

Q27488963-A16265BF-4449-474C-84AB-617E8EFD1F7A

P407

Q27488963-B45B46EA-D483-4A09-B4E0-2937BD08AC46

P433

Q27488963-188FEEA3-B09E-4D48-87B3-B593DA97B423

P478

Q27488963-0BE1D53E-710E-46C7-8140-E4DD298EE28F

P50

Q27488963-70A75FCA-2A5E-408C-9626-CD1DE819C38F

Q27488963-9C09192E-A54D-47CE-BE1C-6CD5F4D4E91C

Q27488963-D085E90F-F95B-4F41-8ADA-BCE1B76733AA

Q27488963-E8B6ABC4-68DA-42FB-BBDF-B6A94369FBB8

P577

Q27488963-E4C6311B-F811-4F90-AA96-2A85A0BFA521

P5875

Q27488963-50AAEA2D-4403-4494-9F72-45D51A514EC6

P698

Q27488963-5DCCEACE-87AB-4E0A-828E-F6674A1ABCE8

P921

Q27488963-41B8B6CE-081B-42E0-A6A3-996F74789B99

Q27488963-6401B034-BB7E-414D-B74B-47C7C8E61827

Q27488963-D6C62F33-4BA4-4C01-BB0C-4FFC879144CA

P932

Q27488963-55757729-D756-49C8-8176-993D397D6490

P3181

P356

P1433

The Journal of Infectious Diseases

P1476

A West Nile Virus DNA Vaccine ...... uring a Phase 1 Clinical Trial

@en

P2093

Brent S Davis

http://www.w3.org/2001/XMLSchema#string

Charla A Andrews

http://www.w3.org/2001/XMLSchema#string

Gwong-Jen J Chang

http://www.w3.org/2001/XMLSchema#string

Ingelise J Gordon

http://www.w3.org/2001/XMLSchema#string

Julie E Martin

http://www.w3.org/2001/XMLSchema#string

Mario Roederer

http://www.w3.org/2001/XMLSchema#string

Martha Nason

http://www.w3.org/2001/XMLSchema#string

Mary E Enama

http://www.w3.org/2001/XMLSchema#string

Michael Fay

http://www.w3.org/2001/XMLSchema#string

Phillip L Gomez

http://www.w3.org/2001/XMLSchema#string

P2860

CCR5 deficiency increases risk of symptomatic West Nile virus infection

A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.

West Nile Virus Discriminates between DC-SIGN and DC-SIGNR for Cellular Attachment and Infection

West Nile virus: a primer for the clinician

West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States.

Clinical characteristics and functional outcomes of West Nile Fever.

Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus.

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention.

P304

1732-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4733334

http://www.w3.org/2001/XMLSchema#string

P356

10.1086/523650

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

196

http://www.w3.org/2001/XMLSchema#string

P50

Theodore C Pierson

Barney S. Graham

P577

2007-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5661125

http://www.w3.org/2001/XMLSchema#string

P698

18190252

http://www.w3.org/2001/XMLSchema#string

P921

West Nile virus

phase I clinical trial

P932

2714735

http://www.w3.org/2001/XMLSchema#string